
Nancy Shulman
Chief Medical Officer
Nancy Shulman joined Bluejay in 2022 as Chief Medical Officer with over 20 years of clinical development experience. Prior to Bluejay, she worked at Roche, Genentech, AbbVie, and most recently at Ambys Medicines, where she was VP of translational medicine. She brings broad clinical development experience ranging from first-in-human and translational studies through Phase 4 studies, including extensive experience in the virology/hepatology disease area, but also in immunology and oncology. She has been a part of multiple INDs and was a key leader on the approvals of the HCV antivirals Viekira Pak®, Viekirax®, and Mavyret®.
Prior to joining industry, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases. She holds a BA in Biochemistry with a minor in Chinese from the University of Texas at Austin and an MD from the University of Kansas. She completed her residency in internal medicine and pediatrics at the University of Chicago and her infectious disease fellowship at Stanford.